Lewis Susan, Sadarangani Manish, Hoe J Claire, Pollard Andrew J
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK.
Expert Rev Vaccines. 2009 Jun;8(6):729-45. doi: 10.1586/erv.09.30.
Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines.
B 群脑膜炎球菌在发达国家造成了大部分的脑膜炎球菌疾病负担。针对 B 群病原体生产有效且安全的疫苗一直受到界定该组细菌的荚膜多糖免疫原性差的阻碍。以往的努力主要集中在外膜囊泡疫苗上，这种疫苗已在克隆性暴发期间成功应用。然而，针对地方性多克隆 B 群脑膜炎球菌疾病的通用疫苗的研发仍在继续。在本综述中，我们重点介绍了外膜囊泡疫苗的最新进展以及重组外膜蛋白疫苗评估方面的进展。
